TACROLIMUS vs TACROLIMUS OINTMENT 0.1%

Compare TACROLIMUS (Tacrolimus) and TACROLIMUS OINTMENT 0.1% (Tacrolimus) — clinical data, side effects, and patient experiences.

TACROLIMUS

Tacrolimus · Immunosuppressant

How it works

12.1 Mechanism of Action Tacrolimus binds to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin (a ubiquitous mammalian intrac...

Approved for

1 INDICATIONS AND USAGE Tacrolimus capsules are calcineurin-inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients receiving allogeneic liver

kidney or heart transplants and pediatric patients receiving allogeneic liver transplants in combination with other immunosuppressants. ( 1.1 ) 1.1 Prophylaxis of Organ Rejection in Kidney

Liver or Heart Transplant Tacrolimus capsules are indicated for the prophylaxis of organ rejection

in adult patients receiving allogeneic kidney transplant [ see Clinical Studies (14.1) ]

OralTablet

TACROLIMUS OINTMENT 0.1%

Tacrolimus · Immunosuppressant

How it works

Other agent

Approved for

INDICATIONS AND USAGE Tacrolimus ointment

both 0.03% and 0.1% for adults

and only 0.03% for children aged 2 to 15 years

or when those treatments are not advisable. Tacrolimus ointment is not indicated for children younger than 2 years of age (see boxed WARNING

TopicalTablet

Quick Comparison

TACROLIMUSTACROLIMUS OINTMENT 0.1%

Drug Class

Immunosuppressant

Route

Oral

Topical

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

TACROLIMUS

Drug Not Working

>10%

Diarrhea

1-10%

Fever

1-10%

TACROLIMUS OINTMENT 0.1%

Drug Not Working

>10%

Diarrhea

1-10%

Fever

1-10%

FDA Warnings

TACROLIMUS

5 WARNINGS AND PRECAUTIONS Not Interchangeable with Extended Release Tacrolimus Products-Medication Errors : Instruct patients or caregivers to recognize the appearance of tacrolimus capsules
5 ) Neurotoxicity: Including risk of Posterior Reversible Encephalopathy Syndrome (PRES), monitor for neurologic abnormalities; reduce or discontinue tacrolimus
9 ) Not recommended for use with sirolimus: Not recommended in liver and heart transplant due to increased risk of serious adverse reactions
1 Lymphoma and Other Malignancies Patients receiving immunosuppressants, including tacrolimus, are at increased risk of developing lymphomas and other malignancies, particularly of the skin

TACROLIMUS OINTMENT 0.1%

WARNING Long-term Safety of Topical Calcineurin Inhibitors Has Not Been Established Although a causal relationship has not been established, rare cases of malignancy (e

Clinical Trial Data

No head-to-head clinical studies found for TACROLIMUS vs TACROLIMUS OINTMENT 0.1%.

TACROLIMUS vs TACROLIMUS OINTMENT 0.1%: What You Should Know

Key Differences

Both TACROLIMUS and TACROLIMUS OINTMENT 0.1% belong to the Immunosuppressant class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients. TACROLIMUS is administered via Oral, whereas TACROLIMUS OINTMENT 0.1% uses Topical. Route of administration can affect onset of action and patient adherence.

Safety Considerations

TACROLIMUS carries 4 FDA warnings. TACROLIMUS OINTMENT 0.1% carries 1 FDA warning. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

EVEROLIMUS vs TACROLIMUS→SIROLIMUS vs TACROLIMUS→CYCLOSPORINE OPHTHALMIC SOLUTION vs TACROLIMUS→CYCLOSPORINE vs TACROLIMUS→MYCOPHENILIC ACID vs TACROLIMUS→AZATHIOPRINE vs TACROLIMUS→

Loading comparison data...

TACROLIMUS vs TACROLIMUS OINTMENT 0.1%

Compare TACROLIMUS (Tacrolimus) and TACROLIMUS OINTMENT 0.1% (Tacrolimus) — clinical data, side effects, and patient experiences.

TACROLIMUS

Tacrolimus · Immunosuppressant

How it works

12.1 Mechanism of Action Tacrolimus binds to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin (a ubiquitous mammalian intrac...

Approved for

1 INDICATIONS AND USAGE Tacrolimus capsules are calcineurin-inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients receiving allogeneic liver

kidney or heart transplants and pediatric patients receiving allogeneic liver transplants in combination with other immunosuppressants. ( 1.1 ) 1.1 Prophylaxis of Organ Rejection in Kidney

Liver or Heart Transplant Tacrolimus capsules are indicated for the prophylaxis of organ rejection

in adult patients receiving allogeneic kidney transplant [ see Clinical Studies (14.1) ]

OralTablet

TACROLIMUS OINTMENT 0.1%

Tacrolimus · Immunosuppressant

How it works

Other agent

Approved for

INDICATIONS AND USAGE Tacrolimus ointment

both 0.03% and 0.1% for adults

and only 0.03% for children aged 2 to 15 years

or when those treatments are not advisable. Tacrolimus ointment is not indicated for children younger than 2 years of age (see boxed WARNING

TopicalTablet

Quick Comparison

TACROLIMUSTACROLIMUS OINTMENT 0.1%

Drug Class

Immunosuppressant

Route

Oral

Topical

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

TACROLIMUS

Drug Not Working

>10%

Diarrhea

1-10%

Fever

1-10%

TACROLIMUS OINTMENT 0.1%

Drug Not Working

>10%

Diarrhea

1-10%

Fever

1-10%

FDA Warnings

TACROLIMUS

5 WARNINGS AND PRECAUTIONS Not Interchangeable with Extended Release Tacrolimus Products-Medication Errors : Instruct patients or caregivers to recognize the appearance of tacrolimus capsules
5 ) Neurotoxicity: Including risk of Posterior Reversible Encephalopathy Syndrome (PRES), monitor for neurologic abnormalities; reduce or discontinue tacrolimus
9 ) Not recommended for use with sirolimus: Not recommended in liver and heart transplant due to increased risk of serious adverse reactions
1 Lymphoma and Other Malignancies Patients receiving immunosuppressants, including tacrolimus, are at increased risk of developing lymphomas and other malignancies, particularly of the skin

TACROLIMUS OINTMENT 0.1%

WARNING Long-term Safety of Topical Calcineurin Inhibitors Has Not Been Established Although a causal relationship has not been established, rare cases of malignancy (e

Clinical Trial Data

No head-to-head clinical studies found for TACROLIMUS vs TACROLIMUS OINTMENT 0.1%.

TACROLIMUS vs TACROLIMUS OINTMENT 0.1%: What You Should Know

Key Differences

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.